SCHEMBL2104541

SCHEMBL2104541

FC1(F)Oc2cc3[nH]c(=S)[nH]c3cc2O1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
HPGD P15428 3/20 0.43
KDM4E B2RXH2 2/20 0.43
TDP1 Q9NUW8 2/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HSD17B10 Q99714 3/20 0.38
PSMB8 P28062 2/20 0.38
POLB P06746 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
HAVCR2 Q8TDQ0 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
CYP3A4 P08684 1/20 0.36
PDE7A Q13946 1/20 0.35
PDE7B Q9NP56 1/20 0.35
GFER P55789 1/20 0.34
SIRT2 Q8IXJ6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12075519 0.68 NPC1 (0.36) ALDH1A1HPGDKDM4ETDP1MEN1
SCHEMBL19275508 0.67 CSNK1E (0.36) ATP4AATP4B
SCHEMBL15553070 0.66 FABP6 (0.49) ALDH1A1MEN1KMT2AATP4AATP4B
SCHEMBL8306086 0.66 CSNK1E (0.42) ATP4AATP4BNOTUM
SCHEMBL8265318 0.66 MAPT (0.46) ALDH1A1HPGDKDM4EMAPTHSD17B10
Bromide SCHEMBL16767404 0.65 FABP6 (0.47) ALDH1A1MEN1KMT2AATP4AATP4B
SCHEMBL7228900 0.64 NOTUM (0.36) GPR3ATP4AATP4BNOTUM
SCHEMBL16789306 0.64 MAPT (0.46) ALDH1A1KDM4ETDP1MAPTCYP3A4
SCHEMBL8759431 0.64 ALPL (0.48) TSHRGPR3NOTUMPIK3CAPIK3CG
SCHEMBL8239476 0.64 TSHR (0.39) TSHRGPR3NOTUMPIK3CAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163768-B2 4-(4-Hydroxy-3-methyl-phenyl)-2,4,6,7,8,9-hexahydro-pyrazolo[3,4-b]-1,7-naphthyridin-5-one; inhibiting Aurora kinase; inhibiting the proliferation of tumor cells; cancer, psoriasis, leukaemia and lupus AVENTIS PHARMA S.A.. (FR) 2012-04-24 US disclosed
EP-1910366-B1 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM AVENTIS PHARMA SA (FR) 2011-08-24 EP disclosed
US-20080261969-A1 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them AVENTIS PHARMA S.A. (FR) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261969-A1 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them DPYD, DHPS, QDPR ALDH1A1 191/4885HPGD 16/4885KDM4E 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.